GOSSHIGH SIGNALRISK10-K

GOSS suffered a failed Phase 3 trial for seralutinib in PAH, causing massive financial deterioration with stockholders' equity turning negative and the company pivoting to damage control mode.

The removal of language about completing the Phase 3 PROSERA study and expecting Q4 2025 results, replaced with discussion of "topline results from PROSERA" announced in February 2026 and needing to "seek to define a regulatory path forward," strongly indicates trial failure. The company has shifted from confidence about regulatory approval to hoping for FDA feedback on any potential path forward, suggesting seralutinib failed to meet primary endpoints.

Comparing 2026-03-17 vs 2025-03-13View on EDGAR →
FINANCIAL ANALYSIS

The financial devastation reflects the failed trial's impact, with stockholders' equity collapsing from $29.5M to negative $122.8M, operating cash flow deteriorating dramatically from -$3.5M to -$171.3M, and revenue plummeting 58% to $48.5M. Total assets declined 45% while net losses tripled to $170.4M, indicating the company burned through substantial resources during the failed trial and now faces severe capital constraints. The 41% increase in current liabilities alongside declining cash suggests mounting financial pressure and potential going concern issues.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-4838.5%
-$3.5M→-$171.3M

Operating cash flow fell 4838.5% — earnings quality concerns; investigate working capital changes and non-cash items.

Stockholders Equity
Balance Sheet
-516.2%
$29.5M→-$122.8M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Net Income
P&L
-201.4%
-$56.5M→-$170.4M

Net income declined 201.4% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-184.9%
-$59.9M→-$170.7M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Accounts Receivable
Balance Sheet
+129.1%
$5.3M→$12.2M

Receivables surged 129.1% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Revenue
P&L
-57.7%
$114.7M→$48.5M

Revenue declined 57.7% — significant demand weakness or market share loss warrants investigation.

Current Assets
Balance Sheet
-45.9%
$309.9M→$167.6M

Current assets declined 45.9% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-45.4%
$315.3M→$172.2M

Total assets contracted 45.4% — asset sales, write-downs, or balance sheet optimization underway.

Current Liabilities
Balance Sheet
+40.9%
$45.0M→$63.4M

Current liabilities surged 40.9% — significant near-term obligations; verify ability to meet short-term debt.

Cash & Equivalents
Balance Sheet
-18.1%
$46.1M→$37.7M

Cash decreased 18.1% — monitor burn rate and upcoming capital needs.

LANGUAGE CHANGES
NEW — 2026-03-17
PRIOR — 2025-03-13
ADDED
As of March 10, 2026, the registrant had 234,696,281 shares of common stock ($0.0001 par value) outstanding.
Our Strategy Our near-term strategy is to focus our resources on advancing seralutinib for the treatment of PAH and to pursue regulatory alignment and potential approval as efficiently as possible.
Based on the totality of data from the Phase 3 PROSERA Study and the Phase 2 TORREY Study, including general consistency across endpoints and within higher risk subgroups, we believe seralutinib demonstrates a risk benefit profile that supports continued regulatory dialogue.
Following our February 2026 announcement of topline results from PROSERA, we are prioritizing (i) completing in-depth analyses of the PROSERA dataset, (ii) engaging with the U.S.
Food and Drug Administration, or FDA, to obtain feedback regarding potential regulatory paths forward, and (iii) evaluating our strategic options and resource allocation as a company, in addition to strengthening our capital structure.
+7 more — sign up free →
REMOVED
As of March 6, 2025, the registrant had 227,221,261 shares of common stock ($0.0001 par value) outstanding.
Richard Aranda, M.D., our Chief Medical Officer, is an experienced clinician and drug developer with previous experience at Bristol Myers Squibb Company, Novo-Nordisk, Inc., Receptos and Celegene Corporation.
Our Strategy We are a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of PH.
Critical components of our business strategy include: Complete the ongoing Phase 3 PROSERA Study of seralutinib in PAH and pursue regulatory approval.
We commenced the registrational Phase 3 PROSERA Study in PAH in the fourth quarter of 2023.
+7 more — sign up free →
MORE RISK SIGNALS
CAPSHIGHCAPS underwent a major business expansion through acquisitions while experiencin...
2026-04-16
KALAHIGHKALA has undergone a dramatic business transformation with massive share dilutio...
2026-04-15
RAINHIGHRain Enhancement Technologies underwent a financial restatement revealing signif...
2026-04-15
POLAHIGHPOLA experienced severe financial deterioration with gross profit turning negati...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →